Clinical Trial Update: Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants [Phase 1]

View source ↗

Summary

Phase 1 trial update on safety and reactogenicity of GSK's inactivated poliomyelitis vaccine (IPV) Poliorix in infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Poliorix (inactivated poliovirus vaccine (IPV))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis | Phase 1 | Status: COMPLETED | Results posted: 2018-12-17